Related Experiment Video

Updated: Aug 6, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Mannose-binding lectin genotype and invasive pneumococcal infection

Leen Moens1, Erna Van Hoeyveld, Willy E Peetermans

  • 1Department of Laboratory Medicine, CDG, University Hospital Leuven, Leuven, Belgium.

Human Immunology
|August 19, 2006
PubMed

Insights

Mannose-binding lectin (MBL) variants are linked to invasive pneumococcal disease risk. MBL structural variants increase the risk, but promoter variants do not significantly alter susceptibility in this study.

Area of Science:

  • Immunology
  • Genetics
  • Infectious Diseases

Background:

  • Invasive pneumococcal disease (IPD) is a significant global health concern, particularly for vulnerable populations.
  • Mannose-binding lectin (MBL) plays a crucial role in innate immunity by mediating complement activation and pathogen opsonization.
  • Genetic variations in MBL alleles have been implicated in varying susceptibility to infections.

Purpose of the Study:

  • To investigate the association between Mannose-binding lectin (MBL) gene variants and the risk of invasive pneumococcal disease (IPD).
  • To determine if specific MBL structural codon and promoter variants influence susceptibility to IPD in a Belgian population.

Main Methods:

  • Genotyping of MBL structural codon variants (52, 54, 57) and promoter variants (-221, -550) was performed.
  • A case-control study design included 63 Belgian patients with IPD and 162 healthy Belgian controls.
  • Data were combined with previously published findings to enhance statistical power.

Main Results:

  • A nonsignificant trend towards increased IPD risk was observed with MBL structural codon variants in the Belgian cohort.
  • Meta-analysis combining current and prior data revealed a small but statistically significant increased risk of IPD associated with MBL structural variants.
  • No significant differences in the distribution of MBL promoter alleles or combined structural-promoter variants were found between IPD patients and controls.

Conclusions:

  • MBL structural variants represent a modest risk factor for invasive pneumococcal disease.
  • MBL promoter variants, including the -221 and -550 alleles, do not appear to significantly influence IPD risk.
  • Further research may elucidate the precise mechanisms linking MBL genetics to pneumococcal pathogenesis.

More Related Videos

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP009208:53

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092

Published on: October 2, 2017

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...